9EP Stock Chart & Stats
€12.00
-€0.20(-1.77%)
At close: 4:00 PM EDT
€12.00
-€0.20(-1.77%)
Day’s Range― - ―
52-Week Range€6.35 - €14.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€303.78M
Enterprise Value€416.67
Total Cash (Recent Filing)€189.51M
Total Debt (Recent Filing)€55.66M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 16, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding29,125,402
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.56Price Target Upside46.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.29
Revenue Forecast (FY)€56.34M
Bulls Say, Bears Say
Bulls Say
Strong Gross ProfitabilityA gross margin near 98% demonstrates that Enanta’s products and partnered economics can generate substantial value after direct costs. If the company converts pipeline programs into commercial assets, this margin profile could support attractive contribution economics and reinvestment.
Improved Balance-Sheet LeverageThe sharp reduction in debt and positive equity base improve financial flexibility compared with prior periods. Lower leverage can reduce balance-sheet pressure and give Enanta more capacity to fund development, manage setbacks, and pursue partnerships while its pipeline matures.
Late-Stage RSV Pipeline ProgressAdvancing zelicapavir into a registrational Phase 2b/3 program represents meaningful progress toward a potentially important commercial asset. Late-stage development can improve partnering prospects and create a clearer path to future milestone, royalty, or product revenue.
Bears Say
Persistent Operating LossesDeeply negative net margins show that Enanta’s current business model is not yet producing sustainable earnings despite strong gross profitability. Continued operating losses can erode equity, restrict internal investment capacity, and increase reliance on future pipeline success.
Ongoing Cash BurnPersistent negative operating and free cash flow means Enanta is not currently self-funding its research and development activities. Even with improved burn versus earlier periods, continued cash use can require external financing and reduce flexibility if clinical or regulatory progress is delayed.
Declining Revenue BaseA shrinking revenue base indicates limited current top-line momentum and makes the company more dependent on future pipeline execution. Without renewed growth from partnered products, milestones, royalties, or new launches, fixed operating costs will remain difficult to absorb.
Enanta Pharmaceuticals News
9EP FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was €6.35 and its highest was €14.20 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Enanta Pharmaceuticals’s market cap is €303.78M.
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 48 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -€0.589 earnings per share for the quarter, missing the consensus estimate of -€0.448 by -€0.141.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -0.64.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 29,125,402 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -€0.589 in its last earnings report, missing expectations of -€0.448. Following the earnings report the stock price went down -2.521%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:9EP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enanta Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€17.56 (46.32% Upside)
€17.56 (46.32% Upside)
Blogger Sentiment
Neutral
DE:9EP Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
9EP Stock 12 Month Forecast
Average Price Target
€17.56
▲(46.32% Upside)
Technical Analysis
Abeona Therapeutics
―
Tectonic Therapeutic
―
Allogene Therapeutics
―
Jade Biosciences
―
Neumora Therapeutics, Inc.
―